We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Addresses Murky Aspects of 180-Day Exclusivity for Generics
FDA Addresses Murky Aspects of 180-Day Exclusivity for Generics
The FDA responded to commonly raised questions about the 180-day exclusivity for generics in a draft guidance document covering everything from patents to forfeitures.